{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:02:40Z","timestamp":1761764560814},"reference-count":38,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2010,2,18]],"date-time":"2010-02-18T00:00:00Z","timestamp":1266451200000},"content-version":"vor","delay-in-days":1685,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Addict"],"published-print":{"date-parts":[[2005,7,9]]},"abstract":"<jats:p>There are several queries on the effectiveness of acamprosate in pharmacoprophylaxis of alcohol dependence despite studies conducted over the last decade regarding its efficacy. In this retrospective chart review, 62 patients with ICD\u201010\u2010diagnosed alcohol dependence who received treatment from an addiction center in India were studied to compare those on acamprosate or naltrexone versus those on no prophylactic drugs with regard to their demographic and clinical background and short\u2010term outcome after treatment. Compared to those on naltrexone or no drugs, significantly more patients on acamprosate came from higher socioeconomic strata and had fewer family \/ marital complications and less comorbid use of opioids and other drugs; however, they also had more liver function impairment and alcoholic liver disease and a higher average duration of relapse in the past (<jats:italic>p<\/jats:italic> &lt; 0.05 or less in each case). The group on no drugs had significantly less family \/ social support (<jats:italic>p<\/jats:italic> = 0.006) and poorer motivation rating (<jats:italic>p<\/jats:italic> &lt; 0.001) than the other two groups on drugs. Intent\u2010to\u2010treat analysis showed that there was a non\u2010significant trend of a higher proportion of acamprosate patients remaining abstinent (77%) than those on naltrexone (36%) or no drug (50%). At follow\u2010up, acamprosate patients had significantly better functioning in several areas. However, because many of the baseline patient characteristics might themselves have influenced the outcome, no conclusion should be drawn from this data regarding the efficacy of the drug. Logistic regression analysis showed that both family\/social support and acamprosate appeared to contribute modestly toward explaining the variance in short\u2010term outcome.<\/jats:p>","DOI":"10.1080\/10550490591006933","type":"journal-article","created":{"date-parts":[[2005,10,6]],"date-time":"2005-10-06T19:52:59Z","timestamp":1128628379000},"page":"381-395","source":"Crossref","is-referenced-by-count":11,"title":["Clinical Characterization of Use of Acamprosate and Naltrexone: Data from an Addiction Center in India"],"prefix":"10.1111","volume":"14","author":[{"given":"Debasish","family":"Basu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Om Prakash","family":"Jhirwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surendra K.","family":"Mattoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,2,18]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1997.tb03370.x"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1992.01820110045007"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1992.01820110040006"},{"key":"e_1_2_5_5_2","unstructured":"Food and Drug Administration.Drug approval\u2010 naltrexone. Available athttp:\/\/www.fda.gov\/cder\/foi\/nda\/99\/75274_Naltrexone.pdf. Accessed May 26 1999."},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1996.01830030039007"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830200071010"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-3057(84)80020-9"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(85)91615-0"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.alcalc.a045057"},{"key":"e_1_2_5_11_2","first-page":"239","article-title":"Double\u2010blind randomized multi\u2010center trial of acamprosate in maintaining abstinence from alcohol","volume":"30","author":"Paille FM","year":"1995","journal-title":"Alcohol Alcohol"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91682-7"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1996.01830080023006"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.171.1.73"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C351"},{"issue":"20","key":"e_1_2_5_16_2","first-page":"42","article-title":"Treatment of alcohol\u2010dependent outpatients with acamprosate: a clinical review","volume":"62","author":"Mason BJ","year":"2001","journal-title":"J C in Psychiatry"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2002.tb04683.x"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2001.tb02356.x"},{"key":"e_1_2_5_19_2","first-page":"259","volume-title":"South East Asia Drug Demand Reduction Report","author":"UNDCP\u2010ROSA","year":"1998"},{"key":"e_1_2_5_20_2","unstructured":"World Health Organization.Global Alcohol Status Report: the South\u2010East Asia Region. Available at:http:\/\/www.who.int\/substance_abuse\/PDFfiles\/global_alcohol_status_report\/TheSouth\u2010EastAsiaRegiontest.pdf. Accessed on 23 Jan 2001."},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1997.tb02966.x"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/35.2.176"},{"key":"e_1_2_5_23_2","first-page":"135","article-title":"Acamprosate in Korean alcohol\u2010dependent patients: a multi\u2010centre, randomized, double\u2010blind, placebo\u2010controlled study","volume":"38","author":"Namkoong K","year":"2003","journal-title":"A coho A coho"},{"key":"e_1_2_5_24_2","first-page":"CD001867","article-title":"Opioid antagonists for alcohol dependence","volume":"2","author":"Srisurapanont M","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_5_25_2","first-page":"419","article-title":"Naltrexone versus acamprosate: one\u2010year follow\u2010up of alcohol dependence treatment","volume":"36","author":"Rubio G","year":"2001","journal-title":"A coho A coho"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.1.92"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2003.tb02873.x"},{"key":"e_1_2_5_28_2","volume-title":"The ICD\u201010 Classification of Mental and Behavioural Disorders: Clinical Description & Diagnostic Guidelines","author":"World Health Organization","year":"1992"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1997.tb02970.x"},{"key":"e_1_2_5_30_2","volume-title":"Statistical Package for the Social Sciences, 10th ed","author":"SPSS Inc","year":"1999"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199753060-00008"},{"key":"e_1_2_5_32_2","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1530-0277.2002.tb02452.x","article-title":"The European NEAT program: an integrated approach using acamprosate and psychosocial support for the prevention of relapse in alcohol\u2010dependent patientswith a statistical modeling of therapy success prediction","volume":"26","author":"Pelc I","year":"2002","journal-title":"Alcohol Clinl Exp Res"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.1995.90911793.x"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1080\/1355621031000117464"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.164.6.741"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1614.2002.01019.x"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.2165\/00126839-200203010-00001"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/37.4.375"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2003.tb02873.x"}],"container-title":["The American Journal on Addictions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1080%2F10550490591006933","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1080\/10550490591006933","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T02:49:26Z","timestamp":1698720566000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1080\/10550490591006933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,9]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,7,9]]}},"alternative-id":["10.1080\/10550490591006933"],"URL":"https:\/\/doi.org\/10.1080\/10550490591006933","archive":["Portico"],"relation":{},"ISSN":["1055-0496","1521-0391"],"issn-type":[{"value":"1055-0496","type":"print"},{"value":"1521-0391","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,9]]}}}